Barclays
LKFT

Barclays’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Barclays’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,000
Closed -$353K – 7047
2019
Q1 		$353K Buy
+3,000
New +$302K ﹤0.01% 4398
2018
Q4 		– Sell
-3,000
Closed -$337K – 7074
2018
Q3 		$337K Buy
+3,000
New +$317K ﹤0.01% 4587

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Barclays's LKFT Position: Q2 2026 in Review

Barclays reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 33% in Q2 2026, selling an estimated $1.68K and leaving 119 shares worth $3.57K. The position accounts for ﹤0.01% of the portfolio, ranked #4811.

Barclays first reported a position in LKFT in Q2 2015 and has held it in 26 quarters since. The position peaked at $12.1M in Q4 2019. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Barclays held 119 shares of Lakefront Biotherapeutics American Depositary Shares worth $3.57K as of Q2 2026.
  • Barclays sold 59 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $1.68K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4811 holding.
  • Barclays first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 26 quarters since.
  • Barclays's Lakefront Biotherapeutics American Depositary Shares position peaked at $12.1M in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.